- Open Access
Endoplasmic reticulum stress enhances the antigen-specific T cell immune responses and therapeutic antitumor effects generated by therapeutic HPV vaccines
Journal of Biomedical Science volume 26, Article number: 41 (2019)
Endoplasmic reticulum stress has a profound effect on cancer cell proliferation and survival, and also has the capacity to activate cells of the adaptive immune system. Multimodal treatment methods that utilize and combine conventional cancer therapies with antigen-specific immunotherapies have emerged as promising approaches for the treatment and control of cancer. However, it is not well known whether endoplasmic reticulum stress-inducing agents can influence the efficacy of tumor antigen-targeting vaccines.
In the past, we developed a therapeutic human papillomavirus (HPV) DNA vaccine that encodes for calreticulin (CRT) linked to the HPV16 E7 antigen (CRT/E7). In this study, we utilize the CRT/E7 and further encode for an endoplasmic reticulum (ER) stress-inducing agent, 3-bromopyruvate (3-BrPA), in a preclinical model, by harnessing its potential to enhance HPV16 E7-specific CD8+ T cell immune responses as well as antitumor effects against E7-expressing tumors (TC-1 cells). E7-specific CD8+ T cells were added to evaluate the cytotoxicity of luciferase-expressing TC-1 tumor cells treated with 3-BrPA in vitro, as measured with an IVIS Luminescence Imaging System. We also determined the levels of ER stress markers in 3-BrPA-treated TC-1 cells. TC-1 tumor-bearing mice were treated with either 3-BrPA (10 mg/kg, intraperitoneal injection) and/or CRT/E7 DNA vaccine (30 μg/mouse).
Treatment of E7-expressing TC-1 tumor cells with 3-BrPA induced significantly higher in vitro cytotoxicity and resulted in upregulation of endoplasmic reticulum stress markers (CHOP and GRP78). More importantly, combination treatment of 3-BrPA and the CRT/E7 DNA vaccine led to improved antigen-specific CD8+ T cell immune responses as well as therapeutic antitumor effects in TC-1 tumor-bearing mice.
Our data indicate that 3-BrPA can enhance therapeutic HPV vaccine potency in generating improved antigen-specific immune responses and antitumor effects. These findings have important implications for future clinical translation and provide novel strategies for the treatment of HPV-associated diseases.
Recently, treatments such as immune checkpoint inhibitors have shown a strong therapeutic effect in several cancer treatments, while other immunotherapies are gradually receiving more attention in cancer therapy [2, 13, 28]. PD-1/PD-L1 and CTLA-4 monoclonal antibodies have significantly improved the survival of metastatic melanoma patients, producing durable responses in about 20–40% of patients when used as monotherapies, and in up to 60% of the combination therapy [24, 32]. PD-1/PD-L1 blockades have achieved impressive clinical results in advanced NSCLC patients, where it is now being investigated in combination with CTLA-4 blockade [11, 22]. Unfortunately, there is concern about the limitations of immune checkpoint therapy, including response heterogeneity, as many patients who receive checkpoint therapy did not demonstrate strong clinical efficacy . Therefore, immunotherapy extends beyond immune checkpoint therapy by employing other immune stimulating strategies such as tumor-associated antigen expressing vaccine therapy and immunogenic cell death, inducing agents that target malignant cells and promote their destruction. DNA vaccines emerge as a practical and attractive approach with great potential to translate to the clinical setting. DNA vaccines are known to be highly stable, and their safety profile has been well-established [3, 18]. DNA vaccines are also easy to prepare and produce at high purity, and allow for multiple administrations . Practically, they are more cost-effective and transportable when compared to other vaccines, such as recombinant protein, tumor cell, or viral vector vaccines. Genes in DNA vaccines can also be designed to encode different antigens as well as various other immunomodulatory molecules to manipulate the resulting immune responses. Despite all the advantages, DNA vaccines have had limited success in producing therapeutic effects against most cancers, due to poor immunogenicity . Therefore, additional strategies are required in an attempt to enhance DNA vaccine potency.
The endoplasmic reticulum (ER) is a specialized organelle that plays a central role in the biosynthesis, correct protein folding, and post-translational modification of secretory and membrane proteins . In cancer, ER stress has the capacity to activate cells of the adaptive immune system . ER stress alone is sufficient to trigger systemic inflammation by proteolytic activation of the transcription factor cyclic-AMP-responsive-element-binding protein H (CREBH) at the ER membrane [31, 35]. ER stress-mediated cell surface presentation of calreticulin (CRT) has emerged as a damage-associated molecular pattern (DAMP) of potential importance in cancer [8, 21]. It is not well-known whether ER stress-inducing agents can influence the efficacy of tumor antigen-targeting vaccines. In our current study, we studied the improvement in efficacy of the CRT/E7 DNA vaccine using the ER stress-inducing agent 3-bromopyruvate (3-BrPA).
Materials and methods
Six-to-8-week-old female C57BL/6 mice were purchased from the National Cancer Institute (Frederick, MD) and housed in the Oncology Center Animal Facility at the Johns Hopkins Medical Institutes (Baltimore, MD). All animal procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals. To ensure that animal discomfort, distress, pain, and injury were kept to a minimum, a maximum of 5 mice were housed in the same cage. All animals were monitored on a daily basis using Johns Hopkins Medical Institutions Animal Care and Use Committee guidelines.
Reagents and cell lines
We have previously generated a human papillomavirus (HPV) E7-expressing tumorigenic cell line, TC-1 , and a firefly luciferase-expressing TC-1 cell line, TC-1-luc  (GenBank Accession LC456627.1). The H-2Db-restricted HPV16 E7aa49–57 peptide, RAHYNIVTF, was synthesized by Macromolecular Resources (Denver, CO) at a purity of ≥80%. PE-conjugated anti-mouse CD8a (clone 53.6.7), FITC-conjugated rat anti-mouse IFN-γ (clone XMG1.2) antibodies were purchased from BD Pharmingen (San Diego, CA). PE-conjugated, HPV16 E749–57 peptide loaded H-2Db tetramer was provided by NIAID tetramer core facility (Atlanta, GA). 3-BrPA, Benzo(a)pyrene (B(a)P, 99% pure), and tricaprylin were purchased from Sigma-Aldrich (St. Louis, MO).
We generated the DNA vaccine encoding calreticulin (CRT) and E7 through methods previously described . We generated pcDNA3-CRT by first amplifying CRT by PCR using rabbit CRT cDNA as the template  and the primers 5′-CCGGTCTAGAATGCTGCTCCCTGTGCCGCT-3′ and 5′-CCGGGAATTCCAGCTCGTCCTTGGCCTGGC-3′. We then cloned the amplified product into the XbaI/EcoRI sites of the pcDNA3 vector (Invitrogen Corp.). To generate the pcDNA3-CRT/E7 vaccine (CRT/E7), we first amplified E7 with a set of primers (5′-GGGGAATTCATGGAGATACACCTA-3′ and 5′-GGTGGATCCTTGAGAACAGATGG-3′) and cloned into the EcoRI/BamHI site of pcDNA3-CRT. We confirmed the accuracy of our DNA constructs with DNA sequencing. We also previously tested the CRT/E7 DNA vaccine against a mock-DNA vaccine control .
Tumor size was monitored by measuring the length (i.e., longest dimension) and width (i.e., shortest dimension) using dial calipers at 3-day intervals. Tumor volume was calculated by the following formula: tumor diameter = 0.5 × (length + width).
In vivo tumor treatment experiment
For in vivo tumor treatment, 1 × 105 TC-1 tumor cells/mouse were subcutaneously (s.c.) injected into the left flank area of 6-to-8-week-old C57BL/6 mice on day 0. After 5 days, the mice were divided into 4 groups (5 mice/group), each receiving a different treatment regimen: Group 1 received no treatment after the TC-1 tumor challenge; Group 2 was treated with 3-BrPA by intraperitoneal (i.p.) injection (5 mg/kg of body weight) at 3-day intervals for a total 4 injections; Group 3 was immunized with the CRT/E7 DNA vaccine schedule at 3-day intervals for a total 4 injections; and Group 4 was both immunized with CRT/E7 and treated with 3-BrPA at 3-day intervals. Mice were monitored twice a week by inspection and palpation. 3-BrPA was prepared as suspensions in PBS. The CRT/E7 DNA vaccine, which has been described previously , was administered via gene gun in the amount of 2 μg/mouse beginning on day 5 at 3-day intervals for a total of 4 vaccinations.
HPV16 E7-specific CD8+ T cell responses in tumor-bearing mice treated with 3-BrPA
Groups of C57BL/6 mice (5 mice/group) were challenged with TC-1 tumor cells and treated with 3-BrPA as described above. To detect HPV16 E7-specific CD8+ T cells in the spleen, splenocytes were harvested from the spleen one week after the last treatment. The cells were stained with FITC-conjugated anti-mouse CD8a (BD Pharmingen, San Diego, CA) and PE-conjugated HPV16 E7 aa49–57 peptide loaded H-2Db tetramer and acquired with FACSCalibur. To detect HPV16 E7-specific CD8+ T cells in the tumor, single cell suspensions were stimulated with HPV16 E7 aa49–57 peptide (1 μg/mL) in the presence of GolgiPlug (BD Pharmingen, San Diego, CA) overnight at 37 °C. The cells were then stained with PE-conjugated antimouse CD8a. After permeabilization and fixation, the cells were stained with FITC-conjugated anti-mouse IFN-γ followed by flow cytometry analysis.
In vitro cytotoxic T cell assay
TC-1-luc tumor cells were added to 24-well plates (5 × 104 cells/well) and incubated overnight at 37 °C. The cells were then treated with 3-BrPA (125 μM) for 24 h and were used as target cells. After washing with PBS, HPV16 E7-specific cytotoxic T lymphocytes (CTLs), generated as previously described , were added to each well except the control well and incubated at 37 °C for 4 h. Target cells incubated without CTLs served as a negative control. Luciferin (15 mg/mL/well) was added to the wells for optical imaging. The expression of luciferase was measured using the IVIS luminescence imaging system series 2000. Bioluminescence signals were acquired for 30 s.
TC-1 tumor cells were seeded to Lab-Tek chamber slide (5 × 104 cells/slide) and then treated with 3-BrPA for 18 h. TC-1 tumor cells were then fixed with 4% formalin. Incubation with primary antibodies against CRT (Abcam, England) was carried out in PBS solution. Secondary Alexa 488 anti-rabbit IgG antibody were used (Life technologic, USA). All sections were counterstained with 4′,6-diamidino-2-phenylindole (DAPI, Life technologic, USA). Images were obtained using a confocal laser scanning microscope (LSM700, ZEISS, Germany).
All experiments were replicated twice independently. All of our data are expressed as means ± standard error (SE) and are representative of at least two independent experiments. Unless indicated, the statistical significance of difference was assessed by two-tailed Student’s t-tests using SPSS version 20.0. The level of significance was set at p < 0.05.
3-bromopyruvate generates potent antitumor effects in TC-1 tumor-bearing mice
We first characterized the antitumor effects of the ER stress agent 3-BrPA, alone or in combination with the CRT/E7 DNA vaccine against the E7-expressing TC-1 tumor model in C57BL/6 mice. The mice were treated according to the regimens outlined in Fig. 1a. The various treatment strategies were initiated 5 days after initial challenge of TC-1 cells. 3-BrPA was injected i.p. at 3-day intervals. The CRT/E7 DNA vaccine was administered at 3-day intervals from day 5 to day 11 by intramuscular (i.m.) injection. As shown in Fig. 1b, mice treated with 3-PrPA and the CRT/E7 vaccine had lower tumor volumes than mice treated with either 3-BrPA or CRT/E7 alone. Furthermore, survival rates of mice treated with the combination of 3-BrPA and CRT/E7 DNA vaccine significantly increased compared to any other treatment regimen (Fig. 1c). These data suggest that a combinatorial treatment with 3-BrPA and the CRT/E7 DNA vaccine elicits synergistic antitumor effects in TC-1 tumor-bearing mice.
TC-1 tumor-bearing mice receiving both 3- bromopyruvate and CRT/E7 DNA generated greater numbers of E7-specific CD8+ T cells
Intracellular cytokine staining and flow cytometric analyses were used to determine the number of IFN-γ-secreting E7-specific CD8+ T cells in tumor-bearing mice treated with 3-BrPA and/or CRT/E7. On day 21 after initial tumor challenge, splenocytes were harvested, isolated, and characterized for E7-specific CD8+ T cells. The combination treatment of 3-BrPA and CRT/E7 generated the highest proportion of E7-specific CD8+ T cells among all treatment groups (Fig. 2). Our data shows that 3-BrPA treatment enhances the generation of E7-specific CD8+ T cells generated by the CRT/E7 DNA vaccine.
3-bromopyruvate increases ER stress markers in TC-1 cells, and elevates the expression of CRT in TC-1 cells
We then investigated the effect of 3-BrPA on ER stress and the expression of CRT in TC-1 cells. The results showed that the expression of ER stress markers and CRT were significantly increased in 3-BrPA-treated TC-1 cells. To evaluate the intensity of ER stress, expression levels of ER stress markers CCAAT-enhancer-binding protein homologous protein (CHOP) and glucose regular protein 78 (GRP78) in TC-1 cells were determined through RT-PCR and Western blots. The results revealed that mRNA levels of GRP78 and CHOP in 3-BrPA-treated TC-1 cells were gradually increased (Fig. 3a). Western blot analyses revealed that protein levels of GRP78 and CHOP in TC-1 cells were also increased from 6 h and 3 h, respectively (Fig. 3b). We also measured the translocation of CRT after treatment of 3-BrPA using immunofluorescence staining and confocal microscopy. Confocal microscopic analyses revealed that 3-BrPA-treated TC-1 cells showed immunofluorescence of CRT in TC-1 cells predominantly in cell membrane areas compared with 3-BrPA-untreated TC-1 cells (Fig. 3c, d).
3-bromopyruvate increases E7-specific T cell cytotoxicity
In order to determine whether 3-BrPA enhanced the danger signal through CHOP and could increase the susceptibility of TC-1 tumor cells to killing by E7-specific CD8+ T cells, we incubated E7-specific CD8+ T cells with TC-1-luc tumor cells with or without pre-treatment with 3-BrPA. Untreated TC-1-luc tumor cells were included as a control. As shown in Fig. 4, TC-1-luc cells treated with 3-BrPA and incubated with E7-specific CD8+ T cells had a much greater decrease in luminescence, indicating greater cytotoxicity, than TC-1-luc cells treated with either 3-BrPA or incubated with E7-specific CD8+ T cells alone. Taken together, our data suggest that TC-1 tumor cells treated with 3-BrPA are able to enhance immunogenic cell death, resulting in their increased susceptibility to killing by E7-specific CD8+ T cells.
In our study, we found that 3-BrPA treatment led to the upregulation of ER stress in TC-1 tumor cells. When cancer cells die, they undergo immunogenic apoptosis characterized by surface-exposed CRT and induced E7-specific CD8+ CTL cytotoxicity. We also found that while 3-BrPA elicited antitumor effects in TC-1 tumor-bearing mice, the combination of 3-BrPA and CRT/E7 created a synergistic effect leading to the generation of significantly more E7-specific CD8+ T cells in the spleen compared to treatment with either treatment alone.
Recently, several DAMPs have been identified as crucial for immunogenic apoptosis. These include surface CRT, surface heat shock protein 90 (HSP90), and secreted ATP [6, 27]. The ER is a specialized organelle that plays a central role in the biosynthesis, correct protein folding, and post-translational modifications of secretory and membrane proteins . However, when the process of protein synthesis and protein folding is out of balance, unfolded and misfolded proteins are accumulated in the ER lumen, which is referred to as ER stress . Cells initiate an adaptive response known as the “unfolded protein response” (UPR) to maintain homeostasis of ER function against an excess of ER stress. ER stress increases in expression of GRP78, a prominent ER-resident chaperone, and CHOP, an apoptotic transcriptional factor [5, 12]. UPR activation functions primarily to protect the cell from ER stress. However, continuous ER stress beyond the threshold of adaptation can trigger apoptosis . Severe ER stress can induce a switch in UPR signaling from pro-survival to pro-apoptotic pathways, which involve the induction of CHOP and the activation of pro-apoptotic kinases such as apoptosis signal regulating kinase 1 (ASK1) and c-Jun-NH2-terminal kinase (JNK). In this experiment, 3-BrPA treatment increased the expression of GRP78 and CHOP in TC-1 cells and increased the expression of CRT on TC-1 cell surfaces. CRT can control the ER to prevent protein misfolding and the aggregation and secretion of incompletely translated major histocompatibility complex I molecules . When apoptosis is induced in tumor cells, CRT is quickly translocated from the ER to the surfaces of cell membranes, leading to immunogenic cell death of tumor cell. When we knocked out CRT, immune responses such as the activation of dendritic cells (DCs) by apoptotic cells also disappeared . In addition to 3-BrPA, ER stress-inducing agents such as bortezomib, oxaliplatin, and oncolytic virus also induce ER stress to induce immunogenic cell death by expressing DAMP signals (e.g. calreticulin) on the cell surface, thereby activating the immune system of the tumor microenvironment . Several biochemical assays have also been developed in the past decade to measure the induction of ER stress, surface exposure of ER/cytosolic chaperones CRT and release of ATP or HMGB1 as markers of immunogenic cell death (ICD) induction. However, none of these assays, even in combination, could discriminate with certainty between ICD and non-ICD inducers. Therefore, ICD evaluation still requires systematic analysis of the generation of an antitumor adaptive immune response. Although we did not check the expression of ER stress markers (e.g. CHOP, GRP78) in the mouse tumor model, we found that the E7-specific CD8 + T cells increased in the spleen and increased ER stress molecules in vitro.
In our experiment, we demonstrate that 3-BrPA may be able to induce the translocation of CRT to the surfaces of tumor cell membranes as a result of ER stress and activate the “eat me” pathway [19, 26, 33]. This “eat me” pathway stimulates the phagocytosis of DCs, which are important antigen presenting cells that initiate T cell-mediated immune responses. Upon recognition and presentation by DCs, tumor antigens trigger T cell-dependent antitumor immune response . The addition of an E7-specific DNA vaccine to these activated DCs further increases the immune activity of DCs and promotes further T cell differentiation. Furthermore, UPR events have been implicated in immune responses, including T cell differentiation and terminal B cell differentiation [9, 25]. These processes eventually promote the differentiation of E7-specific T cells and consequently induces killing of E7-expressing TC-1 cells, resulting in the delay of tumor growth. Those results showed that 3-BrPA and E7-specific DNA vaccine combination therapy can induce specifically sensitized CD8+ T lymphocytes with reconstructed immune pattern within the tumor.
In summary, the results of our study suggest that treatment of tumor-bearing mice with 3-BrPA may create potentially potent immune-mediated therapeutic antitumor effects not only through enhanced tumor-specific immunity, but also through an increased susceptibility of tumor cells to antigen-specific CD8+ T cell-mediated killing. Thus, our study serves as an important foundation for the future clinical application of 3-BrPA in cancer treatment and immunotherapy.
Availability of data and materials
All data recorded for this study was performed at the Johns Hopkins Medical Institutes.
Apoptosis signal regulating kinase 1
CCAAT-enhancer-binding protein homologous protein
Cyclic-AMP-responsive-element-binding protein H
Cytotoxic T lymphocytes
Damage-associated molecular pattern
Glucose regular protein 78
Heat shock protein 90
Unfolded protein response
Bettigole SE, Glimcher LH. Endoplasmic reticulum stress in immunity. Annu Rev Immunol. 2015;33:107–38.
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.
Cheng MA, Farmer E, Huang C, Lin J, Hung CF, Wu TC. Therapeutic DNA vaccines for human papillomavirus and associated diseases. Hum Gene Ther. 2018;29(9):971–96.
Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 2001;108(5):669–78.
Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, Mao C, Ye R, Wang M, Pen L, Dubeau L, Groshen S, Hofman FM, Lee AS. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 2008;68(2):498–505.
Eggleton P, Bremer E, Dudek E, Michalak M. Calreticulin, a therapeutic target? Expert Opin Ther Targets. 2016;20(9):1137–47.
Faitova J, Krekac D, Hrstka R, Vojtesek B. Endoplasmic reticulum stress and apoptosis. Cell Mol Biol Lett. 2006;11(4):488–505.
Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, Annaert W, Golab J, de Witte P, Vandenabeele P, Agostinis P. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012;31(5):1062–79.
Gass JN, Gifford NM, Brewer JW. Activation of an unfolded protein response during differentiation of antibody-secreting B cells. J Biol Chem. 2002;277(50):49047–54.
Gaut JR, Hendershot LM. The modification and assembly of proteins in the endoplasmic reticulum. Curr Opin Cell Biol. 1993;5(4):589–95.
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L. Nivolumab plus Ipilimumab in lung Cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–104.
Huong PT, Moon DO, Kim SO, Kim KE, Jeong SJ, Lee KW, Lee KS, Jang JH, Erikson RL, Ahn JS, Kim BY. Proteasome inhibitor-I enhances tunicamycin-induced chemosensitization of prostate cancer cells through regulation of NF-kappaB and CHOP expression. Cell Signal. 2011;23(5):857–65.
Jung CY, Antonia SJ. Tumor immunology and immune checkpoint inhibitors in non-small cell lung Cancer. Tuberc Respir Dis (Seoul). 2018;81(1):29–41.
Kepp O, Semeraro M, Bravo-San Pedro JM, Bloy N, Buque A, Huang X, Zhou H, Senovilla L, Kroemer G, Galluzzi L. eIF2alpha phosphorylation as a biomarker of immunogenic cell death. Semin Cancer Biol. 2015;33:86–92.
Kim D, Gambhira R, Karanam B, Monie A, Hung CF, Roden R, Wu TC. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine. 2008;26(3):351–60.
Li Y, Zeng X, He L, Yuan H. Dendritic cell activation and maturation induced by recombinant calreticulin fragment 39-272. Int J Clin Exp Med. 2015;8(5):7288–96.
Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56(1):21–6.
MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis. 1998;178(1):92–100.
Martinon F. Targeting endoplasmic reticulum signaling pathways in cancer. Acta Oncol. 2012;51(7):822–30.
Michalak M, Corbett EF, Mesaeli N, Nakamura K, Opas M. Calreticulin: one protein, one gene, many functions. The Biochemical journal. 1999;344(Pt 2):281–92.
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61.
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016;375(19):1823–33.
Rufo N, Garg AD, Agostinis P. The unfolded protein response in immunogenic cell death and Cancer immunotherapy. Trends Cancer. 2017;3(9):643–58.
Sasadeusz J, Kelly H, Szer J, Schwarer AP, Mitchell H, Grigg A. Abnormal cervical cytology in bone marrow transplant recipients. Bone Marrow Transplant. 2001;28(4):393–7.
Scheu S, Stetson DB, Reinhardt RL, Leber JH, Mohrs M, Locksley RM. Activation of the integrated stress response during T helper cell differentiation. Nat Immunol. 2006;7(6):644–51.
Soto-Pantoja DR, Wilson AS, Clear KY, Westwood B, Triozzi PL, Cook KL. Unfolded protein response signaling impacts macrophage polarity to modulate breast cancer cell clearance and melanoma immune checkpoint therapy responsiveness. Oncotarget. 2017;8(46):80545–59.
Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood. 2007;109(11):4839–45.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.
Verfaillie T, Garg AD, Agostinis P. Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Lett. 2013;332(2):249–64.
Voeltz GK, Rolls MM, Rapoport TA. Structural organization of the endoplasmic reticulum. EMBO Rep. 2002;3(10):944–50.
Wheeler MC, Rizzi M, Sasik R, Almanza G, Hardiman G, Zanetti M. KDEL-retained antigen in B lymphocytes induces a proinflammatory response: a possible role for endoplasmic reticulum stress in adaptive T cell immunity. J Immunol (Baltimore, Md : 1950). 2008;181(1):256–64.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbe C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56.
Xu Q, Chen C, Lin A, Xie Y. Endoplasmic reticulum stress-mediated membrane expression of CRT/ERp57 induces immunogenic apoptosis in drug-resistant endometrial cancer cells. Oncotarget. 2017;8(35):58754–64.
Yang Y, Li XJ, Chen Z, Zhu XX, Wang J, Zhang LB, Qiang L, Ma YJ, Li ZY, Guo QL, You QD. Wogonin induced calreticulin/annexin A1 exposure dictates the immunogenicity of cancer cells in a PERK/AKT dependent manner. PLoS One. 2012;7(12):e50811.
Zhang K, Shen X, Wu J, Sakaki K, Saunders T, Rutkowski DT, Back SH, Kaufman RJ. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell. 2006;124(3):587–99.
The authors would like to acknowledge Ms. Lucy Wangaruro for providing additional administrative assistance.
This study was supported by the Korea University R&D Activation Fund (K1325241).
Ethics approval and consent to participate
The housing and handling of mice follow guidelines established by Johns Hopkins Medical Institutions Animal Care and Use Committee and the National Institutes of Health. The Oncology Center Animal Facility has full-time veterinary support through the Department of Comparative Medicine. Animals are monitored daily for infection and other illnesses by trained animal technicians. The criteria include: infection, failure to thrive, perceived pain, respiratory distress, etc. Research support services include training classes and the capacity for full post-mortem analysis is available on request. Only trained laboratory personnel and animal technicians were allowed to handle laboratory animals. All individuals handling mice were registered to protocols at the Johns Hopkins Animal Care and Use Committee.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.